Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 196

Similar articles for PubMed (Select 19440186)

1.

Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans.

Dumont GJ, Kramers C, Sweep FC, Touw DJ, van Hasselt JG, de Kam M, van Gerven JM, Buitelaar JK, Verkes RJ.

Clin Pharmacol Ther. 2009 Aug;86(2):160-6. doi: 10.1038/clpt.2009.62. Epub 2009 May 13.

PMID:
19440186
2.

Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers.

Dumont GJ, van Hasselt JG, de Kam M, van Gerven JM, Touw DJ, Buitelaar JK, Verkes RJ.

J Psychopharmacol. 2011 Apr;25(4):478-89. doi: 10.1177/0269881110376687. Epub 2010 Sep 3.

PMID:
20817749
3.

Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.

Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME.

J Pharmacol Exp Ther. 2012 Feb;340(2):286-94. doi: 10.1124/jpet.111.188425. Epub 2011 Oct 27.

4.

Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.

Shen EY, Ali SF, Meyer JS.

Neuropharmacology. 2011 Dec;61(8):1183-92. doi: 10.1016/j.neuropharm.2011.07.002. Epub 2011 Jul 13.

5.

Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology.

Dumont GJ, Kramers C, Sweep FC, Willemsen JJ, Touw DJ, Schoemaker RC, van Gerven JM, Buitelaar JK, Verkes RJ.

J Psychopharmacol. 2010 Feb;24(2):165-74. doi: 10.1177/0269881108100020. Epub 2008 Dec 12.

PMID:
19074534
6.

Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Freedman RR, Johanson CE, Tancer ME.

Psychopharmacology (Berl). 2005 Dec;183(2):248-56. Epub 2005 Nov 9.

PMID:
16163516
8.

Δ9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys.

Taffe MA.

Neuroscience. 2012 Jan 10;201:125-33. doi: 10.1016/j.neuroscience.2011.11.040. Epub 2011 Nov 29.

9.

THC Prevents MDMA Neurotoxicity in Mice.

Touriño C, Zimmer A, Valverde O.

PLoS One. 2010 Feb 10;5(2):e9143. doi: 10.1371/journal.pone.0009143.

10.

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.

Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, de la Torre R.

J Pharmacol Exp Ther. 2007 Dec;323(3):954-62. Epub 2007 Sep 21.

11.

Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol).

Lansbergen MM, Dumont GJ, van Gerven JM, Buitelaar JK, Verkes RJ.

Psychopharmacology (Berl). 2011 Feb;213(4):745-56. doi: 10.1007/s00213-010-2031-4. Epub 2010 Oct 6.

12.

Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.

Liechti ME, Vollenweider FX.

Eur Neuropsychopharmacol. 2000 Jul;10(4):289-95.

PMID:
10871712
13.

The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.

Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME.

Clin Pharmacol Ther. 2011 Aug;90(2):246-55. doi: 10.1038/clpt.2011.78. Epub 2011 Jun 15.

PMID:
21677639
14.

Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM.

Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77. doi: 10.1016/j.euroneuro.2008.04.008. Epub 2008 Jun 10.

PMID:
18544469
15.

MDMA attenuates THC withdrawal syndrome in mice.

Touriño C, Maldonado R, Valverde O.

Psychopharmacology (Berl). 2007 Jul;193(1):75-84. Epub 2007 Mar 27.

PMID:
17387458
16.

Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial.

Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J.

Ann Intern Med. 2000 Dec 19;133(12):969-73.

PMID:
11119398
17.

Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Mas M, Farré M, de la Torre R, Roset PN, Ortuño J, Segura J, Camí J.

J Pharmacol Exp Ther. 1999 Jul;290(1):136-45.

18.

Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?

Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J.

Biol Psychiatry. 2002 May 1;51(9):766-9.

PMID:
11983191
19.

α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans.

Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME.

J Clin Psychopharmacol. 2013 Oct;33(5):658-66. doi: 10.1097/JCP.0b013e3182979d32.

PMID:
23857311
20.

Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.

Hunault CC, Mensinga TT, de Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, Leenders ME, Meulenbelt J.

Psychopharmacology (Berl). 2008 Dec;201(2):171-81. doi: 10.1007/s00213-008-1260-2. Epub 2008 Aug 10.

PMID:
18695931
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk